小児科臨床ピクシス　9　川崎病のすべて　全訂新版

出版社： 中山書店
著者：
発行日： 2015-04-08
分野： 臨床医学：内科  >  小児科学一般
ISBN： 9784521740959
シリーズ： 小児科臨床ピクシス
電子書籍版： 2015-04-08 （全訂新版第1刷）
書籍・雑誌
≪全国送料無料でお届け≫
取寄せ目安：8～14営業日

8,800 円(税込)

購入する
電子書籍
章別単位での購入はできません
ブラウザ、アプリ閲覧

8,800 円(税込)

購入する

商品紹介

初版から6年近く経ったいまも川崎病の患者は毎年1万人を超え，発熱時の鑑別診断に欠かせない疾患である．疫学調査からみた特性，免疫グロブリン不応例に対する抗サイトカイン療法，遺伝コンソーシアムの設立，免疫学的な病態解析，川崎病既往児への移行期医療など，川崎病に関する基礎から診療，フォローまで幅広く取り上げ，「すべて」のタイトル名にふさわしい改訂．

目次

  • 小児科臨床ピクシス　9　川崎病のすべて　全訂新版

    ―目次―

    １章　疫学
    　　疫学調査の歴史
    　　疫学調査：年次推移，地域特異性
    　　諸外国の川崎病：疫学的特徴
    　　発生数の季節変動
    　　疫学調査にみる年少例・年長例の特徴
    　　血液・生化学データ

    ２章　遺伝
    　　疫学調査からみた遺伝的背景
    　　川崎病の遺伝学的特徴

    ３章　病因
    　　病因説の変遷
    　　自然免疫と川崎病の発症
    　　川崎病と抗原感作
    　　腸内細菌叢
    　　川崎病とサイトカインプロファイル
    　　川崎病の分子マーカー

    ４章　診断
    　　診断の手引き：改訂5版
    　　川崎病のバイタルサインと非特異的臨床症状の重要性
    　　鑑別診断
    　　不全型の特徴と診断
    　　川崎病以前の川崎病
    　　神経症状

    ５章　急性期治療
    　　急性期治療のガイドライン
    　　急性期の電解質
    　　急性期の肝機能
    　　免疫グロブリン療法のメカニズム
    　　ステロイド療法
    　　ウリナスタチン療法
    　　血漿交換療法
    　　インフリキシマブ療法
    　　インフリキシマブ療法のメカニズム
    　　シクロスポリン療法

    ６章　心血管後遺症
    　　　　ガイドライン（2013年改訂版）解説
    　急性期
    　　冠動脈病変：病理
    　　冠動脈病変：生理
    　　抗血栓・抗凝固療法のメカニズム
    　　巨大冠動脈瘤：トータルケア
    　　巨大冠動脈瘤：自然歴
    　　巨大冠動脈瘤：抗凝固療法
    　　巨大冠動脈瘤：外科的治療
    　遠隔期
    　　心血管病変の自然歴（オーバービュー）
    　　冠動脈病変：病理
    　　冠動脈病変：生理
    　　血管内皮機能
    　　カテーテル治療
    　　冠動脈バイパス術
    　　冠動脈バイパス術の長期予後
    　　動脈硬化病変：進行予防の生活管理　
    　　川崎病と予防接種
    　　川崎病既往患者の妊娠・分娩に関する諸問題
    　　川崎病既往児の患者管理：川崎病急性期カード

    ７章　画像診断
    　　心機能評価
    　　心電図検査
    　　X線検査
    　　心エコー図検査
    　　三次元心エコー図検査
    　　冠動脈造影検査
    　　肝動脈CT造影検査
    　　MRI検査
    　　核医学検査
    　　血管内超音波検査、光干渉断層法

この書籍の参考文献

参考文献のリンクは、リンク先の都合等により正しく表示されない場合がありますので、あらかじめご了承下さい。

本参考文献は電子書籍掲載内容を元にしております。

1章 疫学

P.5 掲載の参考文献
1) 柳川洋ほか編. 川崎病の疫学-30年間の総括. 東京 : 診断と治療社 ; 2002.
 
2) 川崎病全国調査担当グループ. 第22回川崎病全国調査成績. 小児科診療 2014 ; 77 : 271-90.
Medical*Online
P.7 掲載の参考文献
1) 柳川洋ほか編. 川崎病の疫学-30年間の総括. 東京 : 診断と治療社 ; 2002.
 
2) Nakamura Y, et al. Epidemiologic features of Kawasaki disease in Japan : results of the 2009-2010 nationwide survey. J Epidemiol 2012 ; 22 : 216-21.
PubMed
3) Nakamura Y, et al. Monthly observation of the number of patients with Kawasaki disease and its incidence rates in Japan : chronological and geographical observation from nationwide surveys. J Epidemiol 2008 ; 18 : 273-9.
PubMed
4) 屋代真弓ほか. 北海道, 四国における10年間の川崎病地域集積性. 日児誌 1999 ; 103 : 832-7.
 
5) 渡辺晃紀ほか. 川崎病患者数に関する検討-栃木県における小児慢性特定疾患認定情報と川崎病全国調査を用いて. 日児誌 2002 ; 106 : 1892-5.
 
P.10 掲載の参考文献
1) Wu MH, et al. State-of-the-art basic and clinical science of Kawasaki disease : the 9th International Kawasaki Disease Symposium 10-12 April 2008, Taipei, Taiwan. Pediatric Health 2008 ; 2 : 405-9.
 
2) 柳川洋ほか. 川崎病疫学の国際比較. 日本臨牀 2008 ; 66 : 237-45.
Medical*Online
3) 中村好一. 世界における川崎病疫学研究の変遷. 柳川洋ほか編. 川崎病の疫学-30年間の総括. 東京 : 診断と治療社 ; 2002. p. 28-35.
 
4) 上原里程. 疫学から (川崎病の本態にせまる-古くて新しい研究から). 小児科診療 2011 ; 74 : 1097-102.
 
P.15 掲載の参考文献
1) 川崎病全国調査担当グループ. 第22回川崎病全国調査成績. 小児科診療 2014 ; 77 : 271-90.
Medical*Online
2) 柳川洋ほか編. 川崎病の疫学 30年間の総括. 東京 : 診断と治療社 ; 2002. p. 68-78.
 
3) Nakamura Y, et al. Monthly observation of the number of patients with Kawasaki disease and its　incidence rates in Japan : chronological and geographical observation from nationwide surveys. J Epidemiol 2008 ; 18 : 273-9.
PubMed
P.16 掲載の参考文献
1) Rodo X, et al. Tropospheric winds from northeastern China carry the etiologic agent of Kawasaki disease from its source to Japan. Proc Natl Acad Sci USA 2014 ; 111 : 7952-7.
PubMed
P.19 掲載の参考文献
1) Chang FY, et al. Characteristics of Kawasaki disease in infants younger than six months of age. Pediatr Infect Dis J 2006 ; 25 : 241-4.
PubMed
2) Stockheim JA, et al. Kawasaki disease in older children and adolescents. J Pediatr 2000 ; 137 : 250-2.
PubMed
3) 大木いずみほか. 川崎病全国調査に基づく主要症状の出現状況に関する初期と現在の比較. 日児誌 2005 ; 109 : 484-91.
 
4) Muta H, et al. Older age is a risk factor for the development of cardiovascular sequelae in Kawasaki disease. Pediatrics 2004 ; 114 : 751-4.
PubMed
5) Uehara R, et al. Serum alanine aminotransferase concentrations in patients with Kawasaki disease. Pediatr Infect Dis J 2003 ; 22 : 839-41.
PubMed
6) 高山順, 柳瀬義男, 川崎富作. MCLSにおけるBCG接種部位の変化についての検討. 日児誌 1982 ; 86 : 567-72.
 
7) Uehara R, et al. Kawasaki disease patients with redness or crust formation at the Bacille Calmette-Guerin inoculation site. Pediatr Infect Dis J 2010 ; 29 : 430-3.
PubMed
8) Pannaraj PS, et al. Failure to diagnose Kawasaki disease at the extremes of the pediatric age range. Pediatr Infect Dis J 2004 ; 23 : 789-91.
PubMed
P.23 掲載の参考文献
1) Koyanagi H, et al. Leukocyte counts in patients with Kawasaki disease : from the results of nation-wide surveys of Kawasaki disease in Japan. Acta Paediatr 1997 ; 86 : 1328-32.
 
2) Harada K. Intravenous gamma-globulin treatment in Kawasaki disease. Acta Paediatr Jpn 1991 ; 33 : 805-10.
PubMed
3) 唐澤賢祐ほか. 川崎病急性期の血小板数の解析-第14回川崎病全国調査成績から. 日児誌 1999 ; 103 : 20-5.
 
4) Uehara R, et al. Serum alanine aminotransferase concentrations in patients with Kawasaki disease. Pediatr Infect Dis J 2003 ; 22 : 839-41.
PubMed
5) Nakamura Y, et al. Case-control study of giant aneurysms due to Kawasaki disease, Pediatr Int 2003 ; 45 : 410-3.
PubMed
6) Egami K, et al. Prediction of resistance to intravenous immuno-globulin treatment in patients with Kawasaki disease. J Pediatr 2006 ; 149 : 237-40.
 
7) Muta H, et al. Serum sodium levels in patients with Kawasaki disease. Pediatr Cardiol 2005 ; 26 : 404-7.
PubMed
8) Nakamura Y, et al. Use of laboratory date to identify risk factors of giant coronary aneurysms due to Kawasaki disease. Pediatr Int 2004 ; 46 : 33-8.
 
9) Kobayashi T, et al. Prediction of intravenous immunoglobulin unresponsiveness in patients with Kawasaki disease. Circulation 2006 ; 113 : 2606-12.
PubMed
10) Koyanagi H, et al. Serum C-reactive protein levels in patients with Kawasaki disease : from the results of nation-wide surveys of Kawasaki disease in Japan. Acta Paediatr 1997 ; 86 : 613-9.
 

2章 遺伝

P.25 掲載の参考文献
1) Fujita Y, et al. Kawasaki disease in families. Pediatrics 1989 ; 84 : 666-9.
PubMed
2) Uehara R, et al. Clinical features of patients with Kawasaki disease whose parents had the same disease. Arch Pediatr Adolesc Med 2004 ; 158 : 1166-9.
PubMed
3) Uehara R, et al. Kawasaki disease in parents and children. Acta Paediatr 2003 ; 92 : 694-7.
PubMed
P.30 掲載の参考文献
1) Onouchi Y, et al. A genomewide linkage analysis of Kawasaki disease : evidence for linkage to chromosome 12. J Hum Genet 2007 ; 52 : 179-90.
PubMed
2) Onouchi Y, et al. ITPKC functional polymorphism associated with Kawasaki disease susceptibility and formation of coronary artery aneurysms. Nat Genet 2008 ; 40 : 35-42.
PubMed
3) Onouchi Y, et al. Common variants in CASP3 confer susceptibility to Kawasaki disease. Hum Mol Genet 2010 ; 19 : 2898-906.
 
4) Khor CC, et al. Genome-wide association study identifies FCGR2A as a susceptibility locus for Kawasaki disease. Nat Genet 2011 ; 43 : 1241-6.
PubMed
5) Onouchi Y, et al. A genome-wide association study identifies three new risk loci for Kawasaki disease. Nat Genet 2012 ; 44 : 517-21.
PubMed
6) Lee YC, et al. Two new susceptibility loci for Kawasaki disease identified through genome-wide association analysis. Nat Genet 2012 ; 44 : 522-5.
PubMed
7) Onouchi Y, et al. ITPKC and CASP3 polymorphisms and risks for IVIG unresponsiveness and coronary artery lesion formation in Kawasaki disease. Pharmacogenomics J 2013 ; 13 : 52-9.
PubMed

3章 病因病態

P.35 掲載の参考文献
1) 川崎富作. 指趾の特異的落屑を伴う小児の急性熱性皮膚粘膜淋巴腺症候群-自験例50例の臨床的観察. アレルギー 1967 ; 16 : 178-222.
Medical*Online
2) 中村好一ほか. 小地域単位に観察した川崎病罹患率の疫学的特性. 日本公衛誌 1984 ; 31 : 539-47.
 
3) 中村好一. 川崎病の地域集積性および時間集積性に関する記述疫学的研究. 日児誌 1987 ; 91 : 896-910.
 
4) 屋代真弓ほか. わが国で最近みられる川崎病の局地的流行. 日本公衛誌 1998 ; 45 : 1068-77.
 
5) 屋代真弓ほか. 最近10年間の川崎病発生の地域・時間集積性の解析. 小児科診療 1999 ; 62 : 419-25.
Medical*Online
6) 屋代真弓ほか. 北海道, 四国における10年間の川崎病地域集積性. 日児誌 1999 ; 103 : 832-7.
 
7) Burns JC, et al. Seasonality and temporal clustering of Kawasaki syndrome. Epidemiology 2005 ; 16 : 220-5.
PubMed
8) Nakamura Y, et al. Monthly observation of the numbers of patients and incidence rates of Kawasaki disease in Japan : chronological and geographical observation from nationwide surveys. J Epidemiol 2008 ; 18 : 273-9.
PubMed
9) 屋代真弓ほか. 第15回川崎病全国調査で観察された年齢別罹患率曲線の変化. 日児誌 2001 ; 105 : 437-41.
 
10) Uehara R, et al. Kawasaki disease in patients and children. Acta Paediatr 2003 ; 92 : 694-7.
PubMed
11) Rodo X, et al. Tropospheric winds from northeastern China carry the etiologic agent of Kawasaki disease from its source to Japan. Proc Natl Acad Sci 2014 ; 111 : 7952-7.
PubMed
12) Onouchi Y, et al. ITPKC functional polymorphism associated with Kawasaki disease susceptibility and formation of coronary artery aneurysms. Nat Genet 2008 ; 40 : 35-42.
PubMed
13) Onouchi Y, et al. Common variants in CASP3 confer susceptibility to Kawasaki disease. Hum Mol Genet 2010 ; 19 : 2898-906.
 
P.40 掲載の参考文献
1) Ikeda K, et al. Unique activation status of peripheral blood mononuclear cells at acute phase of Kawasaki disease. Clin Exp Immunol 2010 ; 160 : 246-55.
PubMed
2) Ling XB, et al. A diagnostic algorithm combining clinical and molecular data distinguishes Kawasaki disease from other febrile illnesses. 2011 ; BMC Medicine 9 : 130.
PubMed
3) Broderick L, et al. Recurrent fever syndromes in patients after recovery from Kawasaki syndrome. Pediatrics 2011 ; 127 : e489-93.
PubMed
4) Nishio H, et al. Nod1 ligands induce site-specific vascular inflammation. Arterioscler Thromb Vase Biol 2011 ; 31 : 1093-9.
 
5) Weiss PF. Pediatric vasculitis. Pediatr Clin North Am 2012 ; 59 : 407-23.
PubMed
P.43 掲載の参考文献
1) Rowley AH, et al. Searching for the cause of Kawasaki disease : cytoplasmic inclusion bodies provide new insight. Nat Rev Microbiol 2008 ; 6 : 394-401.
PubMed
2) 三浦大. 川崎病急性期におけるIgA免疫反応と合成抗体を用いた関連抗原の検出. 日本小児循環器学会雑誌 2008 ; 24 : 3-10.
Medical*Online
3) 松原知代. リンパ球・単球から (川崎病の本態にせまる-古くて新しい研究から). 小児科診療 2011 ; 74, 1109-13.
 
4) Rowley AH, et al. Detection of antigen in bronchial epithelium and macrophages in acute Kawasaki disease by use of synthetic antibody. J Infect Dis 2004 ; 190 : 856-65.
PubMed
5) Rowley AH, et al. Ultrastructural, immunofluorescence, and RNA evidence support the hypothesis of a "new" virus associated with Kawasaki disease. J Infect Dis 2011 ; 203 : 1021-30.
PubMed
P.47 掲載の参考文献
1) Nagata S, et al. Immunohistochemical studies on small intestinal mucosa in Kawasaki disease. Pediatr Res 1993 ; 33 : 557-63.
PubMed
2) Yamashiro Y, et al. Selective increase of V beta 2+ T cells in the small intestinal mucosa in Kawasaki disease. Pediatr Res 1996 ; 39 : 264-6.
PubMed
3) Yamashiro Y, et al. Microbiologic studies on the small intestine in Kawasaki disease. Pediatr Res 1996 ; 39 : 622-4.
PubMed
4) Yeung RSM. Pathogenesis and treatment of Kawasaki disease. Cunr Opin Rheumatol 2005 ; 17 : 617-23.
 
5) Zhu J, et al. Antibodies to human heat-shock protein 60 are associated with the immune component of atherogenesis. Circulation 2001 ; 103 : 1071-5.
 
6) Nagata S, et al. Heat-shock proteins and superantigenic properties of bacteria from the gastrointestinal tract of patients with Kawasaki disease. Immunology 2009 ; 128 : 511-20.
PubMed
7) Southwood S, et al. Several common HLA-DR types share largely overlapping peptide binding repertoires. J Immunol 1998 ; 160 : 3363-73.
PubMed
8) Nagata S, et al. Antimicrobial therapy using sulfamethoxazole trimethoprim for Kawasaki disease patients unresponsive to intravenous immunoglobulin. Open Journal of Pediatrics 2011 ; 1 : 27-9.
 
9) Yokota S, et al. Presence in Kawasaki disease of antibodies to mycobacterial heat-shock protein 65 and autoantibodies to epitopes of human HSP65 cognate antigen. Clin Immunol Immunopathol 1993 ; 67 : 163-70.
PubMed
P.51 掲載の参考文献
1) Sundel RP. Kawasaki disease. In : Cassidy JT, et al, editors. Textbook of Pediatric Rheumatology. 6th ed. Philadelphia : WB Saunders ; 2010. p. 505-23.
 
2) Takahashi K, et al. Kawasaki disease as a systemic vasculitis in childhood. Ann Vasc Dis 2010 ; 3 : 173-81.
PubMed
3) Matsubara T, et al. Immunological profile of peripheral blood lymphocytes and monocytes/macrophages in Kawasaki disease. Clin Exp Immunol 2005 ; 141 : 381-7.
PubMed
4) Galeotti C, et al. Kawasaki disease : aetiopathogenesis and therapeutic utility of intravenous immunoglobulin. Autoimmun Rev 2010 ; 9 : 441-8.
PubMed
5) Orenstein JM, et al. Three linked vasculopathic processes characterize Kawasaki disease : a light and transmission electron microscopic study. PLoS One 2012 ; 7 : e38998.
PubMed
6) Mori M, et al. Efficacy of plasma exchange therapy for Kawasaki disease intractable to intravenous gamma-globulin. Mod Rheumatol 2004 ; 14 : 43-7.
PubMed
7) Sonoda K, et al. Infliximab plus plasma exchange rescue therapy in Kawasaki disease. J Pediatr 2014 ; 164 : 1128-32.
PubMed
P.55 掲載の参考文献
1) Mori M, et al. Efficacy and limitation of infliximab treatment for children with Kawasaki disease intractable to intravenous immunoglobulin therapy : report of an open-label case series. J Rheumatol 2012 ; 39 : 864-7.
 
2) 阿部淳. ピンポイント川崎病-サイトカインと病態. 小児内科 2014 ; 46 : 722-6.
 
3) Shimizu M, et al. Distinct cytokine profiles of systemic-onset juvenile idiopathic arthritis-associated macrophage activation syndrome with particular emphasis on the role of interleukin-18 in its pathogenesis. Rheumatology (Oxford) 2010 ; 49 : 1645-53.
PubMed
4) Takahara T, et al. Serum IL-18 as a potential specific marker for differentiating systemic juvenile idiopathic arthritis from incomplete Kawasaki disease. Rheumatol Int 2015 ; 35 (1) : 81-4. doi : 10.1007/s00296-014-3059-2. Epub 2014 Jun 12.
 
P.59 掲載の参考文献
1) 阿部淳. 川崎病とサイトカイン. 日本臨床 2014 ; 72 : 1548-53.
Medical*Online
2) Kollmann TR, et al. Innate immune function by Toll-like receptors : distinct responses in newborns and the elderly. Immunity 2012 : 37 : 771-83.
PubMed
3) Shimizu C, et al. Differential expression of miR-145 in children with Kawasaki disease. PLoS One 2013 ; 8 (3) : e58159.
 
4) Kentsis A, et al. Urine proteomics for discovery of improved diagnostic markers of Kawasaki disease. EMBO Mol Med 2013 ; 5 : 210-20.
PubMed
5) Reindel R, et al. CD84 is markedly up-regulated in Kawasaki disease arteriopathy. Clin Exp Immunol 2014 ; 177 : 203-11.
PubMed
6) Sleeper LA, et al. Evaluation of Kawasaki disease risk-scoring systems for intravenous immunoglobulin resistance. J Pediatr 2011 ; 158 : 831-5.
PubMed
7) Wang Y, et al. Evaluation of intravenous immunoglobulin resistance and coronary artery lesions in relation to Th1/Th2 cytokine profiles in patients with Kawasaki disease. Arthritis Rheum 2013 ; 65 : 805-14.
PubMed
8) 阿部淳, 松田明生. 川崎病における治療反応性とバイオマーカー. 日本臨床免疫学雑誌 2013 ; 36 : 27-34.
 
9) 名郷直樹. 風邪クルズス. 東京 : メディカルサイエンス社 : 2014.
 

4章 診断

P.65 掲載の参考文献
1) 川崎富作. 指趾の特異的落屑を伴う小児の急性熱性皮膚粘膜淋巴症候群. アレルギー 1967 ; 16 : 178-222.
 
2) Ayusawa M, et al. Revision of diagnostic guidelines for Kawasaki disease (the 5th revised edition). Pediatr Int 2005 ; 47 : 232-4.
PubMed
3) 中村好一ほか. 川崎病研究グループ. 第18回川崎病全国調査成績. 小児科診療 2006 ; 69 : 281-92.
Medical*Online
4) 東田有加ほか. 発熱を認めず冠動脈拡大を来した不全型川崎病の1例. Progress in Medicine 2012 ; 32 : 1407-11.
Medical*Online
5) 吉田寿雄ほか. 発症時有意な発熱と炎症所見を認めなかったが, 冠動脈瘤を形成した1例. Progress in Medicine 2006 ; 26 : 1545-8.
Medical*Online
6) 中村彰利ほか. 発熱を認めず, 冠動脈瘤を形成した主要症状3/6の川崎病不全型の1例. Progress in Medicine 2006 ; 26 : 238.
Medical*Online
7) 吉野篤範ほか. 発熱なく冠動脈拡張を来した川崎病と思われる2症例の検討. 日小誌 2011 ; 15 : 674.
 
8) Tashiro N, et al. Ultrasonographic evaluation of cervical lymph nodes in Kawasaki disease. Pediatrics 2002 ; 109 (5) : E77-7.
PubMed
9) 小田裕造ほか. 川崎病に発症した環軸椎回旋位固定の1例. 整形・災害外科 2009 ; 52 : 1563-5.
 
10) 欠田恭輔ほか. 頸部リンパ節炎に環軸椎回旋位固定を来たした1例. 大阪府済生会中津病院年報 (0918-5771) 2004 ; 14 : 235-7.
 
P.69 掲載の参考文献
1) Bonafide CP, et al. Development of heart and respiratory rate percentile curves for hospitalized children. Pediatrics 2013 ; 131 : e1150-7. doi : 10.1542/peds. 2012-2443. Epub 2013 Mar 11.
 
2) Thompson M, et al. Deriving temperature and age appropriate heart rate centiles for children with acute infections. Arch Dis Child 2009 ; 94 : 361-5.
PubMed
3) Nijman RG, et al. Derivation and validation of age and temperature specific reference values and centile charts to predict lower respiratory tract infection in children with fever : prospective observational. BMJ 2012 ; 345 : e4224.
PubMed
4) Baker AL. Associated symptoms in the ten days prior to diagnosis of Kawasaki disease. J Pediatr 2009 ; 154 : 592-5. e2.
 
P.74 掲載の参考文献
1) 厚生労働省川崎病研究班. 川崎病診断の手引き. 改訂5版. 2002.
 
2) 緒方昌平, 石井正浩. 川崎病診断の進歩. 日本臨牀 2008 ; 6 : 301-6.
 
3) 佐地勉ほか. 川崎病類似疾患. 小児科 2000 ; 41 : 554-64.
 
4) 鮎沢衛. 川崎病急性期の臨床経過と特徴. 日本臨牀 2014 ; 9 : 1563-76.
Medical*Online
5) Latio GA, et al. Macrophage activation syndrome in the acute phase of Kawasaki disease. J Pediatr Hematol Oncol 2010 ; 32 : 527-31.
 
P.79 掲載の参考文献
1) Newburger JW, et al. Diagnosis, treatment, and long-term management of Kawasaki disease : a statement for health professionals from the committee on rheumatic fever, endocarditis, and Kawasaki disease. Council on cardiovascular disease in young, American Heart Association. Circulation 2004 ; 110 : 2747-71.
 
2) Sonobe T, et al. Prevalence of coronary artery abnormalities in incomplete Kawasaki disease. Pediatr Int 2007 ; 49 : 421-6.
PubMed
3) 清澤伸幸ほか. 川崎病不全例の再調査について. Progress in Medicine 2003 ; 23 : 1752-6.
 
4) 大木いずみほか. 川崎病全国調査に基づく主要症状の出現状況に関する初期と現在の比較. 日児誌 2005 ; 109 : 484-91.
 
5) Yellen ES, et al. Performance of 2004 American Heart Association recommendations for treatment of Kawasaki disease. Pediatrics 2010 ; 125 : e234-41.
PubMed
6) Yu JJ, et al. Perivascular brightness of coronary arteries in Kawasaki disease. J Pediatr 2011 ; 159 : 454-7.
PubMed
7) Anderson MS, et al. Delayed diagnosis of Kawasaki syndrome : an analysis of the problems. Pediatrics 2005 ; 115 : e428-33.
PubMed
P.83 掲載の参考文献
1) 泉仙助ほか. 最近金沢市内に流行せる一種の猩紅熱様発疹性熱性病に就て. 日児誌 1929 ; 347 : 667-89.
 
2) Fanney GC Jr. Erythema multiforme exudativum : Stevens-Johnson syndrome. Cardiovascular and central system involvement. J Pediatr 1949 ; 34 : 195-203.
PubMed
3) Shulman ST. The first reported case of Kawasaki disease? J Pediatr 1999 ; 135 : 532.
PubMed
4) 藤川俊夫. フエール氏病の一症例. 小児科診療 1953 ; 28 : 281-3.
 
5) Munro-Faure H. Necrotizing arteritis of the coronary vessels in infancy : case report and review of the literature. Pediatrics 1959 ; 23 : 914-26.
PubMed
6) Shibuya N, et al. Kawasaki disease before Kawasaki at Tokyo University Hospital. Pediatrics 2002 ; 110 : (2PT1)(e17).
 
7) 渋谷紀子. 川崎病発見前の川崎病. 小児科診療 2006 ; 69 : 950-5.
Medical*Online
P.86 掲載の参考文献
1) Terasawa K, et al. Neurological complication in Kawasaki disease. Brain Dev 1983 ; 5 : 371-4.
PubMed
2) Takanashi J, et al. Kawasaki disease complicated by mild encephalopathy with a reversible splenial lesion (MERS). J Neurol Sci 2012 ; 315 : 167-9.
 
3) Knott PD, et al. Sensorineural hearing loss and Kawasaki disease : a prospective study. Am J Otolaryngol 2001 ; 22 : 343-8.
PubMed
4) Ichiyama T, et al. Cerebral hypoperfusion during acute Kawasaki disease. Stroke 1998 ; 29 : 1320-1.
PubMed
5) Ichiyama T, et al. An immunoglobulin agent (IVIG) inhibits NF-κB activation in cultured endothelial cells of coronary arteries in vitro. Inflamm Res 2004 ; 53 : 253-6.
 
6) Poon LKH, et al. Facial nerve palsy and Kawasaki disease. HKMJ 2000 ; 6 : 224-6.
 

5章 急性期治療

P.92 掲載の参考文献
1) 日本小児循環器学会学術委員会 (編集責任者 : 佐地勉). 川崎病急性期治療のガイトライン (2012年改訂版). 日小循誌 2012 ; 28 (Suppl 3) : S1-S28.
 
2) Saji T. et al. Safety and effectiveness of intravenous immunoglobulin preparations for the treatment of Kawasaki disease. Progress in Medicine 2012 ; 32 : 1369-75.
 
3) Kobayashi T, et al. Efficacy of immunoglobulin plus prednisolone for prevention of coronary artery abnormalities in severe Kawasaki disease (RAISE study) : a randomised, open-label, blinded-end-points trial. Lancet 2012 ; 379 (9826) : 1613-20.
 
4) Takahashi K, et al. Pathological study of postcoronary arteritis in adolescents and young adult : with reference to the relationship between sequelae of Kawasaki disease and atherosclerosis. Pediatr Cardiol 2001 ; 22 : 138-42.
 
5) 佐地勉. 急性期川崎病への抗サイトカイン療法 (抗TNFα製剤Infliximab). 山口徹ほか編. Annual Rcview循環器 2011. 東京 : 中外医学社 ; 2011, p. 331-6.
 
P.95 掲載の参考文献
1) Laxer RM, Petty RE. Hyponatremia in Kawasaki disease. Pediatrics 1982 ; 70 : 655.
PubMed
2) 中林佳信, 清水次子. 川崎病に合併する低ナトリウム血症. 日本小児腎臓病学会雑誌 2002 ; 15 : 83-7.
Medical*Online
3) Watanabe T, et al. Hyponatremia in Kawasaki disease. Pediatr Nephrol 2006 ; 21 : 778-81.
PubMed
4) Shin JI, et al. Kawasaki disease and hyponatremia. Pediatr Nephrol 2006 ; 21 : 1490-1.
PubMed
5) Yoshimura K, et al. N-terminal pro-brain natriuretic peptide and risk of coronary artery lesions and resistance to intravenous immunoglobulin in Kawasaki disease. J Pediatr 2013 ; 162 : 1205-9.
PubMed
6) Dahdah N, et al. Natriuretic peptide in Kawasaki disease : the myocardial perspective. Diagnostics 2013 ; 3 : 1-12.
PubMed
7) Kaneko K, et al. Immunoglobulin preparations affect hyponatremia in Kawasaki disease. Eur J Pediatr 2010 ; 169 : 957-60.
PubMed
P.97 掲載の参考文献
1) 藤井喜充. <川崎病の超音波> 胆嚢腫大. 小児内科 2006 ; 38 : 1859-62.
 
2) 何啓暉. 小児における胆嚢, 胆管, 門脈の超音波学的検索 第2編-川崎病における胆嚢, 胆道の超音波学的検討. 日児誌 1987 ; 91 : 2808-11.
 
3) Edwards KM, et al. Intrahepatic cholangitis associated with mucocutaneous lymph node syndrome. J Pediatr Gastroenterol Nutr 1985 ; 4 : 140-2.
PubMed
4) Mercer S, Carpenter B. Surgical complications of Kawasaki disease. J Pediatr Surg 1981 ; 16 : 444-8.
PubMed
P.100 掲載の参考文献
1) Furusho K, et al. High-dose intravenous gammaglobulin for Kawasaki disease. Lancet 1983 ; 322 : 1359.
 
2) Muta H, et al. Late Intravenous immunoglobulin treatment in patients with Kawasaki disease. Pediatrics 2012 ; 129 : e291.
PubMed
3) 永田智. 川崎病におけるガンマグロブリン療法. 小児リウマチ性疾患診療における最近の知見. リウマチ科 2011 ; 46 : 629-35.
 
4) Abe J, et al. Elevated granulocyte colony-stimulating factor levels predict treatment failure in patients with Kawasaki disease. J Allergy Clin Immunol 2008 ; 122 : 1008-13.
PubMed
5) Khor CC, et al. Genome-wide association study identifies FCGR2A as a susceptibility locus for Kawasaki disease. Nat Genet 2011 ; 13 : 1241-6.
 
6) Ogata S, et al. Treatment response in Kawasaki disease is associate with sialylation levels of endogenous but not therapeutic intravenous immunoglobulin G. PLoS One 2013 ; 8 : e81448.
 
P.104 掲載の参考文献
1) Inoue Y, et al. A multicenter prospective randomized trial of corticosteroids in primary therapy for Kawasaki disease : clinical course and coronary outcome, J Pediatr 2006 ; 149 : 336-41.
PubMed
2) Newburger JW, et al. Randomized trial of pulsed corticosteroid therapy for primary treatment of Kawasaki disease. N Engl J Med 2007 ; 356 : 663-75.
PubMed
3) Ogata S, et al. Corticosteroid pulse combination therapy for refractory Kawasaki disease : a randomized trial. Pediatrics 2012 ; 129 : e17-23.
PubMed
4) Kobayashi T, et al. Efficacy of immunoglobulin plus prednisolone for prevention of coronary artery abnormalities in severe Kawasaki disease (RAISE study) : a randomised, open-label, blinded-end-points trial. Lancet 2012 ; 379 : 1613-20.
 
5) Kobayashi T, et al. Prediction of intravenous immunoglobulin unresponsiveness in patients with Kawasaki disease. Circulation 2006 ; 113 : 2606-12.
PubMed
6) Egami K, et al. Prediction of resistance to intravenous immunoglobulin treatment in patients with Kawasaki disease. J Pediatr 2006 ; 149 : 237-40.
PubMed
7) Sano T, et al. Prediction of non-responsiveness to standard high-dose gamma-globulin therapy in patients with acute Kawasaki disease before starting initial treatment. Eur J Pediatr 2007 ; 166 : 131-7.
PubMed
P.108 掲載の参考文献
1) 佐地勉ほか. 日本小児循環器学会研究委員会研究課題「川崎病急性期治療のガイドライン」 (平成24年改訂版). 日本小児循環器学会雑誌 2012 ; 28 : s1-s28.
 
2) 金井貴志ほか. ウリナスタチン療法. 小児内科 2014 ; 46 : 763-7.
Medical*Online
3) Nakatani K, et al. Inhibitory effect of serine protease inhibitors on neutrophil-mediated endothelial cell injury. J Leukoc Biol 2001 ; 69 : 241-7.
PubMed
4) Kanai T, et al. Ulinastatin, a urinary trypsin inhibitor, for the initial treatment of patients with Kawasaki disease : a retrospective study. Circulation 2011 ; 124 : 2822-8.
PubMed
5) 川村陽一ほか. 川崎病における血中ウリナスタチン濃度の動態に関する検討. 新薬と臨牀 2002 ; 51 : 463-6.
Medical*Online
P.111 掲載の参考文献
1) 城宏輔ほか. 川崎病における血漿交換の効果. 小児科診療 1984 ; 47 : 354-62.
 
2) Mori M, et al. Predictors of coronary artery lesions after intravenous gamma-globulin treatment in Kawasaki disease. J Pediatr 2000 ; 137 : 177-80.
PubMed
3) Imagawa T, et al. Plasma exchange for refractory Kawasaki disease. Eur J Pediatr 2004 ; 163 : 263-4.
PubMed
4) 伊藤秀一ほか. γグロブリン不応性川崎病への血漿交換療法. 日本小児腎不全学会雑誌 2007 ; 27 : 115-6.
 
5) 日比野健一ほか. 川崎病治療に関する多施設共同研究. 日児誌 2008 ; 112 : 1227-32.
 
6) Hokosaki T, et al. Long-term efficacy of plasma exchange treatment for refractory Kawasaki disease. Pediatr Int 2012 : 99-103.
PubMed
7) Harada T, et al. A report of two cases of Kawasaki disease treated with plasma exchange. Ther Apher Dial 2008 ; 12 : 176-9.
PubMed
8) Fujimaru T, et al. Decreased levels of inflammatory cytokines in immunoglobulin resistant Kawasaki disease after plasma exchange. Cytokine 2014 Jul 28. pii : S1043-4666 (14) 00213-0. doi : 10.1016/j. cyto. 2014. 07. 003. [Epub ahead of print]
 
P.115 掲載の参考文献
1) Furukawa S, et al. Serum levels of p60 soluble tumor necrosis factor receptor during acute Kawasaki disease. J Pediatr 1994 ; 124 : 721-5.
PubMed
2) Burns JC, et al. Infliximab treatment for refractory Kawasaki syndrome. J Pediatr 2005 ; 146 : 662-7.
PubMed
3) Hirono K, et al. Expression of myeloid-related protein-8 and -14 in patients with acute Kawasaki disease. J Am Coll Cardiol 2006 ; 48 : 1257-64.
PubMed
4) Hirono K, et al. Infliximab reduces the cytokine-mediated inflammation but does not suppress cellular infiltration of the vessel wall in refractory Kawasaki disease. Pediatr Res 2009 ; 65 : 696-701.
 
5) Ye F, et al. Neutrophil-derived S100A12 is profoundly upregulated in the early stage of acute Kawasaki disease. Am J Cardiol 2004 ; 94 : 840-4.
PubMed
6) 日本小児循環器学会学術委員会川崎病急性期治療のガイドライン作成委員会. 川崎病急性期治療のガイドライン (平成24年改訂版). 2012.
Medical*Online
P.119 掲載の参考文献
1) Burns JC, et al. Infliximab treatment for refractory Kawasaki syndrome. J Pediatr 2005 ; 146 : 662-7.
PubMed
2) Burns JC, et al. Infliximab treatment of intravenous immunoglobulin-resistant Kawasaki disease. J Pediatr 2008 ; 153 : 833-8.
PubMed
3) Hirono K, et al. Infliximab reduces the cytokine-mediated inflammation but does not suppress cellular infiltration of the vessel wall in refractory Kawasaki disease. Pediatr Res 2009 ; 65 : 696-701.
 
4) Ogihara Y, et al. Transcriptional regulation by infliximab therapy in Kawasaki disease patients with immunoglobulin resistance. Pediatr Res 2014 ; 76 : 287-93.
PubMed
5) Tremoulet AH, et al. Infliximab for intensification of primary therapy for Kawasaki disease : a phase 3 randomised, double-blind, placebo-controlled trial. Lancet 2014 ; 383 : 1731-8.
PubMed
P.124 掲載の参考文献
1) Kobayashi T, et al. Efficacy of immunoglobulin plus prednisolone for prevention of coronary artery abnormalities in severe Kawasaki disease : a prospective, randamised, open, blinded-endpoint trial. Lancet 2012 ; 379 (9826) : 1613-20.
PubMed
2) 日本小児循環器学会学術委員会 川崎病急性期治療のガイドライン作成委員会. 川崎病急性期治療のガイドライン (平成24年改訂版). 小児循環器学会雑誌 2012 ; 28 (Suppl 3) ; S1-S28.
 
3) Raman V, et al. Response of refractory Kawasaki disease to pulse steroid and cyclosporine A therapy. Pediat Infect Dis 2001 ; 20 (6) : 635-7.
 
4) Onouchi Y, et al. ITPKC functional polymorphism associated with Kawasaki disease susceptibility and formation of coronary artery aneurysms. Nat Genet 2008 ; 40 (1) : 35-42.
PubMed
5) Onouchi Y, et al. ITPKC and CASP3 polymorphism and risks for IVIG unresponsiveness and coronary artery lesion formation in Kawasaki disease. Pharmacogenomics J 2013 ; 13 (1) : 52-9.
PubMed
6) Suzuki H, et al. Marker of T-cell activation is elevated in refractory Kawasaki disease. Pediatr Int 2010 ; 52 (5) : 785-9.
PubMed
7) Suzuki H, et al. Cyclosporin A treatment for Kawasaki disease refractory to initial and additional intravenous immunoglobulin. Pediat Infect Dis J 2011 ; 30 : 871-6.
 
8) Hamada H, et al. Inflammatory cytokine profiles during cyclosporine treatment for immunoglobulin-resistant Kawasaki disease. Cytokine 2012 ; 60 (3) : 681-5.
PubMed
9) Tremoulet AH, et al. Calcineurin inhibitor treatment of intravenous immunoglobulin-resistant Kawasaki disease. J Pediatr 2012 ; 161 (3) : 506-12. e1.
 

6章 心臓血管後遺症

P.131 掲載の参考文献
1) 日本循環器学会学術委員会合同研究班. 川崎病心臓血管後遺症の診断と治療に関するガイドライン (2013年改訂版). http://www.j-circ.or.jp/guideline/pdf/JCS2013_ogawas_h.pdf
 
2) Smith SC Jr, et al. ACC/AHA/SCAI 2005 guideline update for percutaneous coronary intervention : A report of the American College of Cardiology/American Heart Association Task Force on Practice of Guidelines (ACC/AHA/SCAI Writing Committee to Update 20001 Guidelines for Percutaneous Coronary Intervention). Circulation 2006 ; 113 : e166-e286. doi : 10.1161/CIRCULATIONAHA. 106. 173220
 
3) 日本循環器学会ガイドライン「小児期心疾患における薬物療法ガイドライン」 http://www.j-circ.or.jp/guideline/pdf/JCS2012_sachi_h.pdf
 
P.135 掲載の参考文献
1) Landing BH, Larson E. Pathological features of Kawasaki disease (mucocutaneous lymph node syndrome). Am J Cardiovasc Pathol 1987 ; 1 : 218-29.
PubMed
2) Naoe S, et al. Kawasaki disease with particular emphasis on arterial lesions. Acta Pathol Jpn 1991 ;　41 : 785-97.
PubMed
3) Amano S, et al. Pathology of Kawasaki disease : II. Distribution and incidence of the vascular lesions. Jpn Circ J 1979 ; 43 : 741-8.
PubMed
4) 増田弘毅ほか. 川崎病 (MCLS) における冠状動脈の病理学的検討-特に冠状動脈炎と動脈瘤の形態発生の関連について. 脈管学 1981 ; 21 : 899-912.
 
5) Takahashi K, et al. Neutrophilic involvement in the damage to coronary arteries in acute stage of Kawasaki disease. Pediatr Int 2005 ; 47 : 305-10.
PubMed
6) Jennette JC, et al. 2012 revised International Chapel Hill Consensus Conference Nomenclature of Vasculitides. Arthritis Rheum 2013 ; 65 : 1-11.
 
P.139 掲載の参考文献
1) Muller WA. Leukocyte-endothelial cell interactions in the inflammatory response. Lab Invest 2002 ; 82 : 521-33.
PubMed
2) Muller WA. Leukocyte-endothelial-cell interactions in leukocyte transmigration and the inflammatory response. Trends Immunol 2003 ; 24 : 327-34.
PubMed
3) 前野伸昭. 川崎病 Q&A. 小児内科 2003 ; 35 : 1489-91.
 
4) 倉林正彦監. 酸化ストレスナビゲーター. 大阪 : メディカルレビュー社 ; 2005. p. 202-3.
 
5) Inamo Y, et al. Immunoreactive polymorphonuclear leukocyte elastase in complex with alpha 1-antitrypsin in Kawasaki disease. Acta Pediatr Jpn 1987 ; 29 : 202-5.
 
6) 川村陽一ほか. ウリナスタチン治療の可能性. 小児科診療 2001 ; 64 : 1165-8.
Medical*Online
7) Takahashi K, et al. Neutrophilic involvement in the damage to coronary arteries in acute stage of Kawasaki disease. Pediatr Int 2005 ; 47 : 305-10.
PubMed
8) 倉林正彦監. 酸化ストレスナビゲーター. 大阪 : メディカルレビュー社, 2005, p. 30-1.
 
9) 直江史郎. 川崎病の血管病変を側面から考える. Prog Med 1995 ; 15 : 1785-9.
 
10) Yahata T, et al. Dynamics of reactive oxygen metabolites and biological antioxidant potential in the acute stage of Kawasaki disease. Circ J 2011 ; 75 (10) : 2453-9.
PubMed
P.145 掲載の参考文献
1) Yamada K, et al. The platelet functions in acute febrile mucocutaneous lymph node syndrome and a trial of prevention for thrombosis by antiplatelet agent. Acta Haematol Jpn 1978 ; 41 : 791-802.
 
2) Shirahata A, et al. Studies on blood coagulation and antithrombotic therapy in Kawasaki disease. Acta Paediatr Jpn 1983 ; 25 : 180-191.
 
3) Taki M, et al. Spontaneous platelet aggregation in Kawasaki disease using the particle counting method. Pediatr Int 2003 ; 45 : 649-52.
PubMed
4) 傳美和子ほか. 川崎病における可溶型P-セクレチンおよび血小板の膜表面に発現したP-セクレチンの臨床意義. 聖マリアンナ医科大学雑誌 1999 ; 27 : 389-98.
 
5) 川崎病心臓血管後遺症の診断と治療に関するガイドライン (2013年改訂版). www.j-circ.or.jp/guideline/pdf/JCS2013_ogawas_h.pdf
 
6) Newburger J, et al. Diagnosis, treatment, and long-term management of Kawasaki disease : a statement for health professionals from the Committee on Rheumatic Fever, Endocarditis and Kawasaki Disease, Council on Cardiovascular Disease in the Young, American Heart Association. Circulation 2004 ; 110 : 2747-71.
 
7) 菅原洋子ほか. 巨大冠動脈瘤の抗血栓療法. 小児科診療 2006 ; 7 : 1039-42.
Medical*Online
8) Suda K, et al. Warfarin treatment in patients with giant coronary aneurysms caused by Kawasaki disease : a multi center study. J Am Coll Cardiol 2007 ; 49 : 264.
 
9) Bertrand ME, et al. Double-blind study of the safety of clopidogrel with and without a loading dose in combination with aspirin compared with ticlopidine in combination with aspirin after coronary stenting : the clopidogrel aspirin stent international cooperative study (CLASSICS). Circulation 2000 ; 102 : 624-9.
PubMed
10) Li JS, et al. Dosing of clopidogrel for platelet inhibition in infants and young children : primary results of the platelet inhibition in children on clopidogrel (PICOLO) trial. Circulation 2008 ; 117 : 553-9.
PubMed
11) Takahashi H, et al. Different contributions of polymorphisms in VKORC1 and CYP2C9 to intra- and inter-population differences in maintenance dose of warfarin in Japanese, Caucasians and African-Americans. Pharmacogenet Genomics 2006 ; 16 : 101-10.
PubMed
12) 日本小児循環器学会研究委員会研究課題「川崎病急性期治療のガイドライン (平成24年改訂版). 日本小児循環器学会雑誌 2012 ; 28 (suppl-3) : 4997-5028.
 
13) Onouchi Z, et al. Long-term changes in coronary artery aneurysms in patients with Kawasaki disease : comparison of therapeutic regimens. Circ J 2005 ; 69 : 265-72.
PubMed
P.149 掲載の参考文献
1) Imai Y, et al. A fatal case of ruptured giant coronary artery aneurysm. Eur J Pedialr 2006 ; 165 : 130-3.
PubMed
2) Harada M, et al. National Japanese survey of thrombolytic therapy selection for coronary aneurysm : intracoronary thrombolysis or intravenous coronary thrombolysis in patients with Kawasaki disease. Pediatr Int 2013 ; 55 : 690-5.
PubMed
3) Suda K, et al. Intermittent heparin infusion in small children with ischemic heart disease caused by Kawasaki disease. Int J Cardiol 2009 ; 133 : 417-9.
 
4) Suda K, et al. Multi-center and retrospective case study of warfarin and aspirin combination therapy in patients with giant coronary aneurysms caused by Kawasaki disease. Circ J 2009 ; 73 : 1319-23.
 
5) Teramachi Y, et al. Flying with giant coronary aneurysms caused by Kawasaki disease. Int J Cardiol 2013 : 165 ; 4964-5
 
P.151 掲載の参考文献
1) 日本循環器学会学術委員会合同研究班. 川崎病心臓血管後遺症の診断と治療に関するガイドライン (2013年改訂版). http://www.j-circ.or.jp/guideline/pdf/JCS2013_ogawas_h.pdf (2014. 8. 25参照).
 
2) Nakamura Y, et al. Case-control study of giant coronary aneurysms due to Kawasaki disease. Pediatr Int 2003 ; 45 : 410-3.
PubMed
3) Tsuda E, et al. Incidence of stenotic lesions predicted by acute phase changes in coronary arterial diameter during Kawasaki disease. Pediatr Cardiol 2005 ; 26 : 73-9.
PubMed
4) Suda K, et al. Multicenter and retrospective case study of warfarin and aspirin combination therapy in patients with giant coronary aneurysms caused by Kawasaki disease. Circ J 2009 ; 73 : 1319-23.
PubMed
5) Suda K, et al. Long-term prognosis of patients with Kawasaki disease complicated by giant coronary aneurysms : a single-institution experience. Circulation 2011 ; 123 : 1836-42.
PubMed
P.155 掲載の参考文献
1) Suzuki A, et al. Active remodeling of the coronary arterial lesions in the late phase of Kawasaki disease : immunohistochemical study. Circulation 2000 ; 101 : 2935-41.
PubMed
2) Fukazawa R, et al. Coronary artery aneurysm induced by Kawasaki disease in children show features typical senescence. Circ J 2007 ; 71 : 709-15.
PubMed
3) Suda K, et al. Long-term prognosis of patients with Kawasaki disease complicated by giant coronary aneurysms : a single-institution experience. Circulation 2011 ; 123 : 1836-42.
PubMed
4) Sugahara Y, et al. Warfarin therapy for giant aneurysm prevents myocardial infarction in Kawasaki disease. Pediatr Cardiol 2008 ; 29 : 398-401.
PubMed
5) Suda K, et al. Multicenter and retrospective case study of warfarin and aspirin combination therapy in patients with giant coronary aneurysms caused by Kawasaki disease. Circ J 2009 ; 73 : 1319-23.
PubMed
6) Harada M, et al. National Japanese survey of thrombolytic therapy selection for coronary aneurysm : intracoronary thrombolysis or intravenous coronary thrombolysis in patients with Kawasaki disease. Pediatr Int 2013 ; 55 : 690-5.
PubMed
P.158 掲載の参考文献
1) Kato H, et al. Long-term consequences of Kawasaki disease : a 10 to 21-year follow-up study of 594 patients. Circulation 1996 ; 94 : 1379-85.
PubMed
2) Suzuki A, et al. Fate of coronary arterial aneurysms in Kawasaki disease. Am J Cardiol 1994 ; 74 : 822-4.
PubMed
3) Suzuki A, et al. Clinical significance of morphologic classification of coronary arterial segmental stenosis due to Kawasaki disease. Am J Cardiol 1993 ; 71 : 1169-73.
PubMed
4) Suzuki A, et al. Indication of aortocoronary bypass for coronary arterial obstruction due to Kawasaki disease. Heart Vessels 1985 ; 1 : 94-100.
PubMed
5) Kato H, et al. Myocardial infarction in Kawasaki disease, clinical analysis in 195 cases, J Pediatr 1986 ; 108 : 923-7.
 
6) Kuramochi Y, et al. Hemodynamic factors of thrombus formation in coronary aneurysms associated with Kawasaki disease. Pediatr Int 2000 ; 42 : 470-5.
PubMed
7) Sugimura T, et al. Intravascular ultrasound of coronary arteries in children : assessment of the wall morphology and the lumen after Kawasaki disease. Circulation 1994 ; 89 : 258-65.
PubMed
P.163 掲載の参考文献
1) Kato H. Kawasaki disease. In : Willerson JT, et al, editors. Cardiovascular Medicine. 3rd ed. London : Springer-Verlag ; 2007. p. 979-94.
 
2) Kato H, et al. Coronary aneurysms in infants and young children with acute febrile mucocutaneous lymph node syndrome. J Pediatr 1975 ; 86 : 892-8.
PubMed
3) Kato H, et al. Long-term consequences of Kawasaki disease. A 10- to 21-year follow-up study of 594 patients. Circulation 1996 ; 94 : 1379-85.
PubMed
4) Sasaguri Y, Kato H. Regression of aneurysms in Kawasaki disease : a pathological study. J Pediatr 1982 ; 100 : 225-31.
PubMed
5) Yamakawa R, et al. Coronary endotherial dysfunction after Kawasaki disease : evaluation by intracoronary injection of acetylcholine. J Am Coll Cardiol 1998 ; 31 : 1074-80.
 
6) Kato H, et al. Adult coronary artery disease probably due to childhood Kawasaki disease. Lancet 1992 ; 340 : 1127-9.
PubMed
7) Kato H, et al. Fate of coronary aneurysms in Kawasaki disease : serial coronary angiography and long-term follow-up study. Am J Cardiol 1982 ; 49 : 1758-66.
PubMed
P.165 掲載の参考文献
1) Takahashi K, et al. Pathological study of postcoronary arteritis in adolescents and young adults : with reference to the relationship between sequelae of Kawasaki disease and atherosclerosis. Pediatr Cardiol 2001 ; 22 : 138-42.
 
2) 高橋啓, 直江史郎. 血栓内の新生血管に関する検討-再疎通血管から動脈様構造形成に至るまでの組織学的観察より. 脈管学 1991 ; 31 : 1146.
 
3) 高橋啓ほか. 他の原因にて死亡した川崎病罹患既往児の病理組織学的検討. Prog Med 1987 ; 7 : 21-5.
 
4) 高橋啓. 瘤を確認できなかった冠状動脈の狭窄性病変への進展の可能性について. Prog Med 2002 ; 22 : 1676-8.
Medical*Online
P.170 掲載の参考文献
1) Naoe S, et al. Pathological observation concerning the cardiovascular lesions in Kawasaki disease. Cardiol Young 1991 ; 1 : 212-20.
 
2) Suzuki A, et al. Active remodeling of the coronary arterial lesions in the late phase of Kawasaki disease : immunohistochemical study. Circulation 2000 ; 101 : 2935-41.
PubMed
3) Takahashi K, et al. Pathological study of postcoronary arteritis in adolescents and young adults : with reference to the relationship between sequelae of Kawasaki disease and atherosclerosis. Pediatr Cardiol 2001 ; 22 : 138-42.
 
4) Suzuki J, et al. Observation of coronary arterial lesion due to Kawasaki disease in the late phase by intravascular ultrasound. Prog Med 1996 ; 16 : 1797-800.
 
5) Ross R. Atherosclerosis : an inflammatory disease. N Engl J Med 1999 ; 340 : 115-26.
PubMed
6) Steinberg D, et al. Beyond cholesterol : modifications of low-density lipoprotein that increase its atherogenicity. N Engl J Med 1989 ; 320 : 915-24.
PubMed
7) Muller, WA. Leukocyte-endothelial cell interactions in the inflammatory response. Lab Invest 2002 ; 82 : 521-33.
PubMed
8) Muller, WA. Leukocyte-endothelial-cell interaction in leukocyte transmigration and the inflammatory response. Trends Immunol 2003 ; 24 : 327-34.
PubMed
9) Kobayashi S, et al. Interaction of oxidative stress and inflammatory response in coronary plaque instability : important role of C-reactive protein. Arterioscler Thromb Vasc Biol 2003 ; 23 : 1398-404.
PubMed
10) Ishii M, et al. Sequential follow-up results of catheter intervention for coronary artery lesions after Kawasaki disease : quantitative coronary artery angiography and intravascular ultrasound imaging study. Circulation 2002 ; 105 : 3004-10.
PubMed
11) Hamaoka K, et al. Evaluation of coronary flow velocity dynamics and flow reserve in patients with Kawasaki disease by means of a Doppler guide wire. J Am Coll Cardiol 1998 ; 31 : 833-40.
 
12) 劉亜黎ほか. 家兎の冠状動脈炎における遊走平滑筋細胞動態と動脈硬化に対する検討. 日児誌 1996 ; 100 : 1453-8.
 
13) Toyokuni S. Reactive oxygen species-induced molecular damage and its application in pathology. Pathol Int 1999 ; 49 : 91-102.
PubMed
14) 二星あゆみ, 濱岡建城. 川崎病血管障害と酸化ストレス-動脈硬化への進展を考える. 吉川敏一編. 別冊医学のあゆみ. 酸化ストレス. ver. 2, フリーラジカル医学生物学の最前線. 東京 : 医歯薬出版 ; 2006. p. 265-9.
 
15) Deng YB, et al. Evaluation by high-resolution ultrasonography of endothelial function in brachial artery after Kawasaki disease and the effects of intravenous administration of vitamin C. Circ J 2002 ; 66 : 908-12.
PubMed
16) Hamaoka A, et al. Effects of HMG-CoA reductase inhibitors on continuous post-inflammatory vascular remodeling late after Kawasaki disease. J Cardiol 2010 ; 56 : 245-53.
PubMed
P.175 掲載の参考文献
1) Dhillon R, et al. Endothelial dysfunction late after Kawasaki disease. Circulation 1996 ; 94 : 2103-6.
PubMed
2) Mitani Y, et al. Impaired endothelial function in epicardial coronary arteries after Kawasaki disease. Circulation 1997 ; 96 : 454-61.
PubMed
3) Yamakawa R, et al. Coronary endothelial dysfunction after Kawasaki disease : evaluation by intracoronary injection of acetylcholine. J Am Coll Cardiol 1998 ; 31 : 1074-80.
PubMed
4) Furuyama H, et al. Assessment of coronary function in children with a history of Kawasaki disease using (15) O-water positron emission tomography. Circulation 2002 ; 105 : 2878-84.
PubMed
5) Niboshi A, et al. Endothelial dysfunction in adult patients with a history of Kawasaki disease. Eur J Pediatr 2008 ; 167 : 189-96.
PubMed
6) Fathi R, Marwick TH. Noninvasive tests of vascular function and structure : why and how to perform them. Am Heart J 2001 ; 141 : 694-703.
PubMed
7) Mitani Y, et al. Elevated levels of high-sensitivity C-reactive protein and serum amyloid-A late after Kawasaki disease : association between inflammation and late coronary sequelae in Kawasaki disease. Circulation 2005 ; 111 : 38-43.
PubMed
P.181 掲載の参考文献
1) Kato H, et al. Long-term consequences of Kawasaki disease. A 10- to 21-year follow-up study of 594 patients. Circulation 1996 ; 94 : 1379-85.
PubMed
2) Ishii M. et al. Guideline for catheter intervention in coronary artery lesion in Kawasaki disease. Pediatr Int 2001 ; 43 : 558-62.
PubMed
3) Ishii M, et al. Sequential follow-up results of catheter intervention for coronary artery lesion after Kawasaki disease : quantitative coronary artery angiography and intravascular ultrasound imaging study. Circulation 2002 ; 105 : 3004-10.
PubMed
4) 循環器病の診断と治療に関するガイドライン. 急性心筋梗塞 (ST上昇型) の診療に関するガイドライン (2013年改訂版). 〔日本循環器学会HPに公開のみ〕
 
5) Badr S, et al. The state of the excimer laser for coronary intervention in the drug-eluting stent era. Cardiovasc Revasc Med 2013 ; 14 : 93-8.
PubMed
6) Murakami T, Tanaka N. The physiological significance of coronary aneurysms in Kawasaki disease. EuroIntervention 2011 ; 7 : 944-7.
PubMed
7) Muta H, Ishii M. Percutaneous coronary intervention versus coronary artery bypass grafting for stenotic lesions after Kawasaki disease. J Pediatr 2010 ; 157 : 120-6.
PubMed
8) Tsuda E, et al. Long-term patency of internal thoracic artery graft for coronary artery stenosis due to Kawasaki disease : comparison of early with recent results in small children. Am Heart J 2007 ; 153 : 995-1000.
PubMed
9) Tsuda E, Kitamura S. National survey of coronary artery bypass grafting for coronary stenosis caused by Kawasaki disease in Japan. Circulation 2004 ; 110 : 1161-6.
 
P.184 掲載の参考文献
1) Kitamura S, et al. Aortocoronary bypass grafting in a child with coronary artery obstruction due to mucocutaneous lymph-node syndrome : report of a case. Circulation 1976 ; 53 : 1035-40.
 
2) Kitamura S, et al. Severe Kawasaki heart disease treated with an internal mammary artery graft in pediatric patients : a first successful report. J Thorac Cardiovasc Surg 1985 ; 89 : 860-6.
PubMed
3) Kitamura S, et al. Excellent patency and growth potential of internal mammary artery grafts in pediatric coronary artery bypass surgery : new evidence for a "live" conduit. Circulation 1988 ; 78 : 1129-39.
 
4) Kitamura S, et al. Twenty-five-year outcome of pediatric coronary artery bypass surgery for Kawasaki disease. Circulation 2009 ; 120 : 60-8.
PubMed
5) Kitamura S, et al. Long-term outcome of myocardial revascularization in patients with Kawasaki coronary artery disease : a multicenter cooperative study. J Thorac Cardiovasc Surg 1994 ; 107 : 663-74.
PubMed
6) Tsuda E, Kitamura S, Cooperative Study group of Japan. National survey of coronary artery bypass grafting for coronary stenosis caused by Kawasaki disease in Japan. Circulation 2004 ; 110 [suppl 1] : II61-6.
 
7) Tsuda E, et al. Competition between native flow and graft flow after coronary artery bypass grafting : impact on indications for coronary artery bypass grafting for localized stenosis with giant aneurysms due to Kawasaki disease. Pediatr Cardiol 2008 ; 29 : 266-70.
PubMed
8) JCS Joint Working Group. Guidelines for diagnosis and management of cardiovascular sequelae in Kawasaki disease (JCS 2008) -digest version. Circ J 2010 ; 74 : 1989-2020.
 
9) Ogawa S, et al. Estimation of myocardial hemodynamics before and after intervention in children with Kawasaki disease. J Am Coll Cardiol 2004 ; 43 : 653-61.
PubMed
10) Senzaki H. Long-term outcome of Kawasaki coronary disease. Circulation 2008 ; 18 : 2763-72.
 
P.187 掲載の参考文献
1) Wakisaka Y, et al. Long-term results of saphenous vein graft for coronary stenosis caused by Kawasaki disease. Circ J 2009 ; 73 : 73-7.
PubMed
2) Tsuda E, et al. Long-term patency of internal thoracic artery grafts for coronary artery stenosis due to Kawasaki disease : comparison of early with recent results in small children. Am Heart J 2007 ; 153 : 995-1000.
PubMed
3) Tsuda E. Coronary artery bypass grafting for coronary artery stenosis caused by Kawasaki disease. Expert Rev Cardiovasc Ther 2009 ; 7 (5) : 533-9.
PubMed
P.189 掲載の参考文献
1) Kavey RE, et al. American Heart Association guidelines for primary prevention of atherosclerotic cardiovascular disease beginning in childhood. Circulation 2003 ; 107 : 1562-6.
PubMed
2) 川崎病心臓血管後遺症の診断と治療に関するガイドライン (2013年改訂版). 日本循環器学会, 日本胸部外科学会, 日本小児科学会, 日本小児循環器学会, 日本心臓病学会合同研究班報告.
 
3) 動脈硬化性疾患診療ガイドライン. 2002年版. 日本動脈硬化学会.
 
4) 動脈硬化性疾患予防ガイドライン. 2007年版. 日本動脈硬化学会.
Medical*Online
5) 動脈硬化性疾患予防ガイドライン. 2012年版. 日本動脈硬化学会.
 
P.193 掲載の参考文献
1) 薗部友良ほか. 川崎病ガンマグロブリン療法後の免疫調査 (麻疹抗体とワクチン接種について). 厚生省心身障害研究「小児慢性疾患のトータルケアに関する研究」. 平成3年度研究報告書. 1992, p. 39-42.
 
2) Miura M, et al. Time interval of measles vaccination on patients with Kawasaki disease treated with additional intravenous immune globulin. Eur J Pediatr 2004 ; 163 : 25-9.
PubMed
3) 岡部信彦監, 米国小児科学会編. R-Book 2009 : 最新感染症ガイド 日本版. 東京 : 日本小児医事出版社 ; 2011, p. 448.
 
4) Advisity Committee on Immunization Practices. General recommendations on immunization, Recommendations of the advisory Committee on Immunization Practices (ACIP). MMWR 1994 ; 43 : 15-8, p. 23-5.
 
5) 佐治勉. 川崎病急性期治療のガイドライン作成委員会編. 川崎病急性期治療のガイドライン (平成24年改訂版). 日小循誌 2012 ; 28 (Suppl 3).
 
P.195 掲載の参考文献
1) 日本循環器学会ほか編. 心疾患患者の妊娠・出産の適応, 管理に関するガイドライン (2010年改訂版).
 
2) 小森暁子ほか. ST低下のある川崎病冠動脈障害合併妊娠の2例. Prog Med 2013 ; 33 : 1495-500.
Medical*Online
3) 津田悦子ほか. 川崎病による冠動脈障害をもつ患者の妊娠・分娩に対する対応. 日本臨床 2014 : 72 (9) : 1687-90.
Medical*Online
4) Tsuda E, et al. Nationwide survey of pregnancy and delivery in patients with coronary arterial lesions caused by Kawasaki disease. Cardiol Young 2006 ; 16 : 173-8.
PubMed
P.199 掲載の参考文献
1) 日本川崎病研究会運営委員会. 川崎病の管理基準 (2002年改訂). 日児誌 2003 ; 107 : 166-7.
 
2) 篠原徹ほか. 経過観察終了が可能な川崎病既往児に対する管理への提言 (案) -管理に関する小委員会報告. Progress in Medicine 2001 ; 21 : 1654-7.
Medical*Online
3) 荻野廣太郎. 川崎病遠隔期管理に関する新たな動き 川崎病カードの導入-「川崎病急性期カード」 (日本川崎病研究会監修) ができるまで. Progress in Medicine 2003 ; 23 : 1806-11.
 

7章 画像診断

P.202 掲載の参考文献
1) Newburger JW, et al. Left ventricular contractility and function in Kawasaki syndrome : effect of intravenous gamma-globulin. Circulation 1989 ; 79 : 1237-46.
PubMed
2) Takeuchi D, et al. Abnormal tissue doppler images are associated with elevated plasma brain natriuretic peptide and increased oxidative stress in acute Kawasaki disease. Circ J 2007 ; 71 : 357-62.
PubMed
3) McCandless RT, et al. Myocardial strain and strain rate in Kawasaki disease. Eur Heart J Cardiovasc Imaging 2013 ; 14 : 1061-8.
PubMed
4) Kaneko K, et al. Prediction of the risk of coronary arterial lesions in Kawasaki disease by brain natriuretic peptide. Pediatr Cardiol 2011 ; 32 : 1106-9.
PubMed
5) Iwashima S, Ishikawa T. B-type natriuretic peptide and N-terminal pro-BNP in the acute phase of Kawasaki disease. World J Pediatr 2013 ; 9 : 239-44.
 
6) Kurotobi S, et al. Brain natriuretic peptide as a hormonal marker of ventricular diastolic dysfunction in children with Kawasaki disease. Pediatr Cardiol 2005 ; 26 : 425-30.
PubMed
7) Maeder M, et al. B-type natriuretic peptide in patients with sepsis and preserved left ventricular ejection fraction. Eur J Heart Fail 2005 ; 7 : 1164-7.
 
8) Yutani C, et al. Cardiac biopsy of Kawasaki disease. Arch Pathol Lab Med 1981 ; 105 : 470-3.
PubMed
9) Harada M, et al, Histopathological characteristics of myocarditis in acute-phase Kawasaki disease. Histopathology 2012 ; 61 : 1156-67.
PubMed
10) Torrent-Guasp F, et al. The structure and function of the helical heart and its buttress wrapping. I : the normal macroscopic structure of the heart. Semin Thorac Cardiovasc Surg 2001 ; 13 : 301-19.
PubMed
P.207 掲載の参考文献
1) 浅井利夫. 急性熱性皮膚粘膜リンパ節症候群 (MCLS) の心臓障害に関する研究-第1編心電図変化について. 日児誌 1976 ; 80 : 60-7.
 
2) 峰田喬臣ほか. MCLSに合併したWPW症候群-MCLSの心電図所見について. 小児科 1977 ; 18 : 79-86.
 
3) 吉武克宏ほか. MCLSにおける心電図の経時的変化. 医療 1980 ; 34 : 1086-9.
Medical*Online
4) 播磨良一ほか. 川崎病の不整脈. 小児内科 1981 ; 13 : 1043-51.
 
5) Fujiwara H. Clinicopathologic study of the conduction systems in 10 patients with Kawasaki's disease (mucocutaneous lymph node syndrome). Am Heart J 1978 ; 96 : 744-50.
PubMed
6) 本田隆文. 急性心筋梗塞とその治療. 小児内科 2009 ; 41 : 116-9.
Medical*Online
7) 加藤裕久ほか. 川崎病心筋梗塞例の検討 川崎病-疫学データのすべて. 日本心臓財団川崎病原因究明委員会編. ソフトサイエンス社 ; 1986, p. 144-9.
 
8) 藤原久義. 川崎病の心・冠動脈病変. 川崎富作ほか編. 川崎病. 東京 : 南江堂 ; 1988, p. 64-7.
 
9) 保崎純郎, 川崎病心臓後遺症. 保崎純郎編著. 小児心電図トレーニング. 東京 : 中外医学社 ; 1988, p. 212.
 
P.211 掲載の参考文献
1) Umezawa T, et al. Chest X-ray finding in the acute phase of Kawasaki disease. Pediatr Radiol 1989 ; 20 : 48-51.
PubMed
2) Moriya S, et al. Peribronchovascular haze : a frequently observed findings on chest X-ray in the acute phase of Kawasaki disease. Jpn J Radiol 2014 ; 32 : 38-43.
 
3)渋谷和俊ほか. 川崎病における肺血管病変の病理組織学的研究. 脈管学 1987 ; 27 : 293-304.
 
4) Ino T, et al. Coronary artery calcification in Kawasaki disease. Pediatr Radiol 1990 ; 20 : 520-3.
PubMed
5) Lapierre C, et al. Follow-up chest X-ray in patients with Kawasaki disease : the significance and clinical application of coronary artery macro-calcification. Pediatr Cardiol 2010 ; 31 : 56-61.
PubMed
6) Nakada T, et al. Coronary arterial calcification in Kawasaki disease. Acta Paediatr Jpn 1991 ; 33 : 443-9.
PubMed
P.216 掲載の参考文献
1) 川崎病心臓血管後遺症の診断と治療に関するガイドライン. Circulation J 2003 ; 67 : 1111-52.
 
2) Hiraishi S, et al. Transthoracic ultrasonic visualization of coronary aneurysm, stenosis, and occlusion in Kawasaki disease. Heart 2000 ; 83 : 400-5.
PubMed
3) Fujiwara H, Hamashima Y. Pathology of the heart in Kawasaki disease. Pediatrics 1978 ; 61 : 100-7.
PubMed
4) 神谷哲郎ほか. 川崎病による冠動脈障害の発生と進展. 循環器研究の進歩 1982 : 5 : 19-27.
 
5) 浅井利夫ほか. 急性熱性皮膚粘膜淋巴節症候群の心臓障害を中心とした臨床. 小児科臨床 1973 ; 26 : 824-30.
Medical*Online
6) Akagi T, et al. Valvular heart disease in Kawasaki syndrome : incidence and natural history. Am Heart J 1990 ; 120 : 366-72.
PubMed
7) Newhurger JW, et al. Diagnosis, treatment, and long-term management of Kawasaki disease : a statement for health professionals from the Committee on Rheumatic Fever, Endocarditis and Kawasaki Disease, Council on Cardiovascular Disease in the Young American Heart Association. Circulation 2004 ; 110 : 2747-71.
 
9) 布施茂登ほか. 小児の心エコー検査による冠動脈内径の標準曲線の作成-LMS法 (歪度, 中央値, 変動係数により分布を変化させる統計学的手法) による. 日児誌 2009 ; 113 : 928-34.
 
10) Dallaire F, et al. New equations and a critical appraisal of coronary artery Z score in healthy children. J Am Soc Echocardiogr 2011 ; 24 : 60-74.
 
11) de Zorzi A, et al. Coronary artery dimensions may be misclassified as normal in Kawasaki disease. J Pediatr 1998 ; 133 : 254-8.
PubMed
8）神谷哲郎ほか．川崎病による冠動脈障害診断の基準化に関する小委員会，厚生省川崎病班会議報告書 ; 1983, p. 1-10.
 
12）新垣義夫ほか．川崎病と大動脈弁閉鎖不全. Prog Med 1993 ； 13 : 1347-50.
Medical*Online
P.218 掲載の参考文献
1) Miyashita M, et al. Usefulness of real-time 3-dimensional echocardiography for the evaluation of coronary artery morphology in patients with Kawasaki disease. J Am Soc Echocardiogr 2007 ; 20 : 930-3. Epub 2007 Jun 6.
 
2) Takuma S, ct a1, Real-time, 3-dimensional echocardiography acquires all standard 2-dimensional images from 2 volume sets : a clinical demonnstration in 45 patients. Am Soc Echocardiogr 1999 ; 12 : 1-6.
 
3) Newburger JW, et al. Diagnosis, treatment, and long-term management of Kawasaki disease : a statement for health professionals from the Committee on Rheumatic Fever, Endocarditis, and Kawasaki Disease, Council on Cardiovascular Disease in the Young, American Heart Association. Circularion 2004 ; 26 : 2747-71.
 
4) Abe O, et al. Quantitative evaluation of coronary artery wall echogenicity by integrated backscatter analysis in Kawasaki disease. J Am Soc Echocardiogr 2010 ; 23 : 938-42.
PubMed
P.227 掲載の参考文献
1) 浅井利夫, 草川三治. MCLSの冠動脈造影所見. 日本医事新報 1974 ; 2594 : 37-40.
 
2) 近藤千里. 小児心血管画像検査の放射線被曝リスクの考え方．日本小児循環器学会雑誌 2009 ; 25 : 659-64.
Medical*Online
3) Sasaguri Y, Kato H. Regression of aneurysms in Kawasaki disease : a pathological study. J Pediatr 1982 ; 100 : 225-31.
PubMed
5) 川崎病心臓血管後遺症の診断と治療に関するガイドライン. 2013年改訂版.
 
6) 富田英ほか. 先天性および小児期発症心疾患に対するカテーテル治療の適応ガイドライン. 日本小児循環器学会雑誌 2012 ; 28 (Suppl 2) : 4997-5040.
 
7) Troianos CA, et al. Special articles : guidelines for performing ultrasound guided vascular cannulation : recommendations of the American Society of Echocardiography and the Society Of Cardiovascular Anesthesiologists. Anesth Analg 2012 ; 114 : 46-72.
 
8) 小柳仁ほか. 新・心臓カテーテル法. 改訂第2版. 東京 : 南江堂 ; 1990.
 
9) 日本腎臓学会. 日本医学放射線学会. 日本循環器学会編. 腎障害患者におけるヨード造影剤使用に関するガイドライン 2012.
 
10) 堀正二 (班長). 循環器疾患における抗凝固・抗血小板療法に関するガイドライン. 2009年改訂版.
 
11) Harada M, et al. National Japanese survey of thrombolytic therapy selection for coronary aneurysm : intracoronary thrombolysis or intravenous coronary thrombolysis in patients with Kawasaki disease. Pediatr Int 2013 ; 55 : 690-5.
PubMed
4）鈴木淳子. 川崎病の冠動脈障害経過観察に心臓カテーテル検査は必須かどうか? -MR冠動脈画像が非侵襲的に示す鮮明かつ豊富な情報のすべて. 心臓 2014 ; 46 : 660-2.
Medical*Online
P.235 掲載の参考文献
1) Sato Y, et al. Detection of coronary artery aneurysms, stenoses and occlusions by multislice spiral computed tomography in adolescents with Kawasaki disease. Circ J 2003 ; 67 : 427-30.
PubMed
2) Kanamaru H, et al. Assessment of coronary artery abnormalities by multislice spiral computed tomography in adolescents and young adults with Kawasaki disease. Am J Cardiol 2005 ; 95 : 522-5.
 
3) 小川俊一ほか. 循環器病の診断と治療に関するガイドライン 日本循環器学会学術委員会合同研究班. 川崎病心臓血管後遺症の診断と治療に関するガイドライン (2013年改訂版) http://www.j-circ.or.jp/guideline/pdf/JCS2013_ogawas_h.pdf (2014年9月30日アクセス)
 
4) 金丸浩ほか. 心臓CT. 日児放誌 2011 ; 27 : 18-29.
 
5) Suzuki A, et al. Clinical significance of morphologic classification of coronary arterial segmental stenosis due to Kawasaki disease. Am J Cardiol 1993 ; 71 : 1169-73.
PubMed
6) Johnson PT, et al. IV contrast infusion for coronary artery CT angiography : literature review and results of a nationwide survey. AJR 2009 ; 192 : W214-W221.
PubMed
7) 金丸浩ほか, 川崎病重症冠動脈障害のマルチスライスコンピューター断層撮影による評価の有用性. J Cardiol 2007 ; 50 : 21-7.
 
P.242 掲載の参考文献
1) Kato H, et al. Long-term consequences of Kawasaki disease : a 10- to 21-year follow-up study of 594 patients. Circulation 1996 ; 94 : 1379-85.
PubMed
2) Schwitter J, et al. MR-IMPACT : comparison of perfusion-cardiac magnetic resonance with singlephoton emission computed tomography for the detection of coronary artery disease in a multicentre, multivendor, randomized trial. Eur Heart J 2008 ; 29 : 480-9.
 
3) Hamon M, et al. Meta-analysis of the diagnostic performance of stress perfusion cardiovascular magnetic resonance for detection of coronary artery disease. J Cardiovasc Magn Reson 2010 ; 12 : 29.
PubMed
4) Kim RJ, et al. The use of contrast-enhanced magnetic resonance imaging to identify reversible myocardial dysfunction. N Engl J Med 2000 ; 343 : 1445-53.
PubMed
5) Beek AM, et al. Delayed contrast-enhanced magnetic resonance imaging for the prediction of regional functional improvement after acute myocardial infarction. J Am Coll Cardiol 2003 ; 42 : 895-901.
PubMed
P.249 掲載の参考文献
1) Kondo C, et al. Detection of coronary artery stenosis in children with Kawasaki disease : usefulness of pharmacologic stress 201Tl myocardial tomography. Circulation 1989 : 80 : 615-24.
PubMed
2) Germano G, et al. Automatic quantitation of regional myocardial wall motion and thickening from gated technetium-99m sestamibi myocardial perfusion single-photon emission computed tomography. J Am Coll Cardiol 1997 ; 30 : 1360-7.
PubMed
3) Karasawa K, et al. Detection of myocardial contractile reserve by low-dose dobutamine quantitative gated single-photon emission computed tomography in patients with Kawasaki disease and severe coronary artery lesions. Am J Cardiol 2003 : 92 : 865-8.
PubMed
4) Koizumi K, et al. [The Japanese Society of Nuclear Medicine, Optimization Committee for Pediatric Nuclear Medicine Studies] Japanese consensus guideline for pediatric nuclear medicine. Ann Nucl Med 2014 ; 28 : 498-503.
PubMed
5) 唐澤賢祐ほか. 川崎病冠動脈狭窄性病変におけるTechnetium-99m Tetrofosmin心筋血流イメージングの至適撮像方法に関する検討. J Cardiol 1997 ; 30 : 331-9.
 
6) Monzen H, et al. Exploring a technique for reducing the influence of scattered rays from surrounding organs to the heart during myocardial perfusion scintigraphy with technetium-99m sestamibi and technetium-99m tetrofosmin. Ann Nucl Med 2006 ; 20 : 705-10.
 
7) 日本アイソトープ協会医学薬学部会核医学イメージング規格化専門委員会. RADIOISOTOPES 1988 ; 37 : 627-32.
 
P.251 掲載の参考文献
1) Sugimura T, et al. Interventional treatment for children with severe coronary artery stenosis with calcification after long-term Kawasaki disease. Circulation 1997 ; 96 : 3928-33.
PubMed
2) Sugimura T, et al. Intravascular ultrasound of coronary arteries in children : assessment of the wall morphology and the lumen after Kawasaki disease. Circulation 1994 ; 89 : 258-65.
PubMed
3) Mitani Y, et al. In vivo plaque composition and morphology in coronary artery lesions in adolescents and young adults long after Kawasaki disease : a virtual histology-intravascular ultrasound study. Circulation 2009 ; 119 : 2829-36.
 
4) Ishii M. Sequential follow-up results of catheter intervention for coronary artery lesions after Kawasaki disease : quantitative coronary artery angiography and intravascular ultrasound imaging study. Circulation 2002 ; 105 : 3004-10.
PubMed
5) Tsuda E. Coronary artery dilatation exceeding 4.0 mm during acute Kawasaki disease predicts a high probability of subsequent late intima-medial thickening. Pediatr Cardiol 2002 ; 23 : 9-14.
 
6) Harris KC, et al. Feasibility of optical coherence tomography in children with Kawasaki disease and pediatric heart transplant recipients. Circ Cardiovasc Imaging 2014 ; 7 : 671-8.
PubMed

書評

最近チェックした商品履歴

Loading...